viewInstem PLC

Instem raises £15.75mln for acquisition opportunities

Broker N+1 Singer will carry out the placing at 435p, which is a 4.4% discount to yesterday’s close.

Instem PLC -

Instem PLC (LON:INS), the clinical data specialist, has raised £15.75mln through a placing alongside an additional secondary sale of £3mln worth of shares by certain directors.

The AIM-listed company said it will use the money for bolt-on acquisitions and more substantial targets.

Broker N+1 Singer carried out the placing through a bookbuild at 435p, or a 4.4% discount to yesterday’s close.

Instem, which specialises in the supply of information technology to the life sciences market, recently reported strong organic revenue growth in 2019.

Revenues during the year were around 13% higher than in 2018 at £25.7mln.

The company was also recently awarded a contract by Biotoxtech, one of the leading research companies in Korea to provide a comprehensive package for preclinical data collection.


Quick facts: Instem PLC

Price: 465 GBX

Market: AIM
Market Cap: £95.24 m

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Instem PLC named herein, including the promotion by the Company of Instem PLC in any Content on the Site, the Company receives from said issuer...


Tech in focus: Instem, Alfa Financial Software and Attraqt

Proactive analyst Richard Jeans takes a look at the UK tech industry and picks three stocks he has been watching this week. Jeans firstly focuses on Instem (LON:INS) which is a software business servicing the global life sciences market, which recently reported a 12% organic growth rate for...

on 2/10/20

2 min read